Clene (NASDAQ:CLNN) Announces Quarterly Earnings Results, Misses Estimates By $0.71 EPS

Clene (NASDAQ:CLNN) issued its quarterly earnings data on Friday. The company reported ($1.08) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.37) by ($0.71), FiscalAI reports. The company had revenue of $0.09 million during the quarter, compared to analysts’ expectations of $0.06 million.

Clene Trading Down 1.2%

Shares of NASDAQ CLNN traded down $0.05 during trading on Friday, reaching $4.14. The company had a trading volume of 58,954 shares, compared to its average volume of 252,360. Clene has a twelve month low of $3.53 and a twelve month high of $13.50. The stock has a 50-day moving average price of $5.63 and a two-hundred day moving average price of $5.64. The stock has a market capitalization of $52.91 million, a PE ratio of -1.29 and a beta of 0.96.

Wall Street Analysts Forecast Growth

Several research analysts have recently issued reports on the company. HC Wainwright reaffirmed a “buy” rating and set a $31.00 price target on shares of Clene in a research note on Monday, May 4th. Weiss Ratings cut shares of Clene from a “sell (d-)” rating to a “sell (e+)” rating in a research note on Thursday, July 30th. D. Boral Capital restated a “buy” rating and set a $23.00 target price on shares of Clene in a research report on Monday, May 4th. Finally, Roth Capital reaffirmed a “buy” rating on shares of Clene in a report on Thursday, May 14th. Six investment analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the company’s stock. According to data from MarketBeat.com, the company has a consensus rating of “Moderate Buy” and a consensus target price of $33.25.

Institutional Investors Weigh In On Clene

Several hedge funds have recently modified their holdings of the company. Jane Street Group LLC acquired a new position in shares of Clene in the second quarter valued at approximately $47,000. Scoggin Management LP grew its stake in Clene by 42.7% in the 2nd quarter. Scoggin Management LP now owns 142,750 shares of the company’s stock worth $558,000 after acquiring an additional 42,750 shares during the period. Geode Capital Management LLC grew its stake in Clene by 8.0% in the 4th quarter. Geode Capital Management LLC now owns 82,079 shares of the company’s stock worth $482,000 after acquiring an additional 6,090 shares during the period. SymBiosis Capital Partners LLC acquired a new position in Clene in the 4th quarter valued at $4,523,000. Finally, Ensign Peak Advisors Inc raised its holdings in Clene by 668.6% in the 4th quarter. Ensign Peak Advisors Inc now owns 114,361 shares of the company’s stock valued at $671,000 after acquiring an additional 99,481 shares during the last quarter. 23.28% of the stock is owned by institutional investors and hedge funds.

Clene Company Profile

Clene (NASDAQ: CLNN), also known as Clene Nanomedicine, is a clinical-stage biopharmaceutical company developing proprietary nanoparticle therapies aimed at treating neurodegenerative and demyelinating disorders. The company’s flagship product, CNM-Au8, is a suspension of catalytic gold nanocrystals designed to enhance cellular energy metabolism, promote remyelination, and reduce oxidative stress. Clene’s platform leverages the unique physicochemical properties of its nanoparticles to support neuronal health, with a focus on diseases that currently lack effective disease-modifying treatments.

Clene’s lead candidate, CNM-Au8, is undergoing multiple clinical trials targeting conditions such as amyotrophic lateral sclerosis (ALS), Parkinson’s disease, and multiple sclerosis (MS).